Tag: Natco cancer

Natco Pharma Q1 net, revenue slump on lower cancer drug sales

Posted on By admin
Natco Pharma Q1 net, revenue slump on lower cancer drug sales

Drugmaker Natco Pharma’s June quarter consolidated net profit slumped 57% year-on-year (YoY) to ₹206.5 crore on the back of lower sales of generic cancer drug Lenalidomide. The profit came on a nearly 43% YoY dip in total revenue to ₹794.4 crore, largely attributable to lower sales earnings from Lenalidomide — generic of once blockbuster cancer…

Read More “Natco Pharma Q1 net, revenue slump on lower cancer drug sales” »

Business

Natco Pharma gets USFDA nod for generic cancer drug, shares rise 4% intra-day

Posted on By admin
Natco Pharma gets USFDA nod for generic cancer drug, shares rise 4% intra-day

Hyderabad-based Indian multinational pharmaceutical and biotechnology company Natco Pharma’s shares were in the spotlight on Monday after it received tentative approval from the U.S. Food and Drug Administration (FDA) for Olaparib, 100 mg, and 150 mg, which are bioequivalent to AstraZeneca Pharmaceuticals’ referenced drug Lynparza used in the treatment of certain types of cancer. The…

Read More “Natco Pharma gets USFDA nod for generic cancer drug, shares rise 4% intra-day” »

Business